What is the dose of Tranexamic acid (TXA) for uterine bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The dose of Tranexamic acid (TXA) for uterine bleeding is 1 g intravenously.

Dosage Details

  • The dose can be repeated if bleeding continues after 30 minutes, or if bleeding restarts within 24 hours of completing the first dose, with a second dose of 1 g intravenously 1.
  • The recommended administration is at a fixed dose of 1 g (100 mg/mL) intravenously at 1 mL/min, given over 10 minutes 1.

Clinical Context

  • TXA should be given in all cases of post-partum haemorrhage, regardless of whether the bleeding is thought to be due to genital tract trauma or for other reasons, including uterine atony 1.
  • The use of TXA is recommended within 3 hours of birth, in addition to standard care for women with clinically diagnosed post-partum haemorrhage following vaginal birth or caesarean section 1.
  • A clinically estimated blood loss of more than 500 mL after vaginal birth or 1000 mL after caesarean section, or any blood loss that is sufficient to compromise haemodynamic stability, is considered a clinically diagnosed post-partum haemorrhage 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Dose of Tranexamic Acid for Uterine Bleeding

The dose of tranexamic acid (TXA) for uterine bleeding varies depending on the specific condition being treated.

  • For heavy menstrual bleeding, the recommended oral dosage is 3.9-4 g/day for 4-5 days starting from the first day of the menstrual cycle 2.
  • For postpartum hemorrhage, the WHO recommends 1 g of tranexamic acid intravenously as soon as possible after giving birth, followed by a second dose if bleeding continues after 30 minutes or restarts within 24 hours since the first dose 3.
  • A study on the optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women proposed an optimal dose of 600 mg in future tranexamic acid efficacy studies to prevent postpartum hemorrhage 4.

Administration Routes and Timing

  • Tranexamic acid can be administered orally or intravenously, depending on the condition being treated.
  • For postpartum hemorrhage, intravenous administration is recommended as soon as possible after giving birth 3.
  • The timing of administration is critical, as tranexamic acid is most effective when given early, ideally within 3 hours of childbirth 3.

Safety and Efficacy

  • Tranexamic acid has been shown to be effective in reducing bleeding-related mortality in women with postpartum hemorrhage 5, 3.
  • The safety profile of tranexamic acid is generally good, with few adverse effects reported 2, 4.
  • However, tranexamic acid is contraindicated in women with active thromboembolic disease or a history of thrombosis or thromboembolism 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tranexamic acid for post-partum haemorrhage: What, who and when.

Best practice & research. Clinical obstetrics & gynaecology, 2019

Research

Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women.

American journal of obstetrics and gynecology, 2021

Research

Tranexamic acid for childbirth: why, when, and for whom.

Expert review of hematology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.